Express Pharma

Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes

It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction and hospitalisation for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes

0 705

Bayer announced the Unit